Keytruda

© GettyImages/Pheelings Media

FDA rebuff for Keytruda in breast cancer indication

By Jane Byrne

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.

(Image: Getty/Monsitj)

Sales of Keytruda leads Merck to strong Q2

By Ben Hargreaves

Sales of immunotherapy treatment, Keytruda, were up by 58% year-on-year, which led Merck to a sales increase of 12% overall compared to 2018.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers